Relay Therapeutics (RLAY) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$91.6 million.
- Relay Therapeutics' Enterprise Value rose 3990.17% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.6 million, marking a year-over-year increase of 3990.17%. This contributed to the annual value of -$124.3 million for FY2024, which is 1353.11% up from last year.
- Per Relay Therapeutics' latest filing, its Enterprise Value stood at -$91.6 million for Q3 2025, which was up 3990.17% from -$113.9 million recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Enterprise Value ranged from a high of -$91.6 million in Q3 2025 and a low of -$354.6 million during Q3 2022
- Over the past 5 years, Relay Therapeutics' median Enterprise Value value was -$151.3 million (recorded in 2023), while the average stood at -$170.0 million.
- Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Enterprise Value was 5913.35% (2021), while the steepest drop was 27348.95% (2021).
- Relay Therapeutics' Enterprise Value (Quarter) stood at -$280.1 million in 2021, then surged by 45.81% to -$151.8 million in 2022, then increased by 5.31% to -$143.7 million in 2023, then grew by 13.53% to -$124.3 million in 2024, then grew by 26.33% to -$91.6 million in 2025.
- Its last three reported values are -$91.6 million in Q3 2025, -$113.9 million for Q2 2025, and -$93.5 million during Q1 2025.